PATENT CLAIM ANALYSIS

Application Number: 15742702
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["435", "006140"]

Abstract:
The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.

Claim (Index 63):
A method according to  claim 62  which comprises:\n (i) administering the agent to a cell, group of cells or an animal model, not a human; and \n (ii) measuring PHGDH expression and/or PHGDH activation in samples derived from the treated and the untreated cells or animal model; and \n (iii) detecting an increase in the expression and/or activation of PHGDH in the treated sample as compared to the untreated sample as an indication of the ability to inhibit or reverse epithelial-to-mesenchymal transition (EMT).

Metadata:
- Claim Count in Document: 71.0
- Percentile: 86.0
- Lexical Diversity: 1.59459
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14398572', '12742546', '14690001', '13320060', '15533049']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6323044127590238
- 35 USC 102 Novelty (BERT): 0.5225265714302605
- Combined Prediction Score: 0.6213266286261475
- Mean Citation Score: 257.888148
- Max Citation Score: 317.90555
- Similarity Product: 194.32190332903264

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test